Design, Synthesis, and Evaluation of Antitumor Activity of Novel Pyrimidine Derivatives Containing Acrylamide and a Cyano Group

被引:0
作者
Chen, Hongjing [1 ,2 ]
Gu, Dongling [1 ,2 ]
Han, Jiahui [1 ,2 ]
Yang, Zichen [1 ,2 ]
Wang, Shihao [1 ,2 ]
Chi, Lingling [1 ,2 ]
Yu, Fuqiang [1 ,2 ]
Wang, Hao [1 ,2 ]
Liu, Hongmin [1 ,2 ,3 ,4 ]
Ke, Yu [1 ,2 ,3 ,4 ]
Zhang, Qiurong [1 ,2 ,3 ,4 ]
机构
[1] Zhengzhou Univ, Sch Pharmaceut Sci, Zhengzhou 450001, Henan, Peoples R China
[2] Inst Drug Discovery & Dev, Zhengzhou 450001, Henan, Peoples R China
[3] State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou 450002, Henan, Peoples R China
[4] Minist Educ, Key Lab Adv Drug Preparat Technol, Zhengzhou 450001, Henan, Peoples R China
基金
中国国家自然科学基金;
关键词
pyrimidine; acrylamide; cyano group; antitumor activity; apoptosis; CANCER STATISTICS; METABOLISM; RESISTANCE; INHIBITORS; THERAPY;
D O I
10.1134/S1068162024605019
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Objective: Based on the observed in vitro antitumor activity, the conformational influence of various substituents at the 2-position of the pyrimidine ring was systematically investigated to develop more effective antitumor pyrimidine analogs. Methods: A series of novel pyrimidine derivatives containing acrylamide and cyano groups were designed and synthesized. Their antiproliferative activities against four human tumor cell lines (MDA-MB-231, MGC-803, PC-3, and A549) were evaluated using the MTT assay. Additionally, colony formation, migration, cell cycle distribution, and apoptosis assays were performed to elucidate the antitumor mechanisms of compound (XVIIIg). Results and Discussion: Compound (XVIIIg) exhibited the strongest inhibitory activity against PC-3 cells, with an IC50 value of 1.50 +/- 0.29 mu M. Cellular assays confirmed that (XVIIIg) significantly suppressed PC-3 cell proliferation and migration, induced G(0)/G(1) cell cycle arrest, and promoted apoptosis. Structural modifications at the 2-position of the pyrimidine ring had a pronounced effect on in vitro antitumor activity. The 4-fluorophenyl (4-F-C6H4) substituent in compound (XVIIIg) contributed to its superior inhibitory effect, suggesting its potential as a lead compound. Conclusions: Among the 21 synthesized compounds, (XVIIIg) demonstrated the most potent antiproliferative and antimigratory activity, along with dose-dependent apoptosis induction in PC-3 cells. These results highlight its promise as a candidate for further development of novel antitumor agents.
引用
收藏
页码:1054 / 1069
页数:16
相关论文
共 44 条
[21]  
Maarouf R.A., 2021, QJM: Int. J. Med, V114, phcab106, DOI [10.1093/qjmed/hcab106.065, DOI 10.1093/QJMED/HCAB106.065]
[22]   Long-term outcomes of surgical resection of lung metastases from colorectal cancer. [J].
Mori, Ryota ;
Kagawa, Yoshinori ;
Yukawa, Yoshiro ;
Toya, Keisuke ;
Takase, Kouki ;
Nose, Yohei ;
Kawai, Kenji ;
Sakamoto, Takuya ;
Naito, Atsushi ;
Murakami, Kohei ;
Katsura, Yoshiteru ;
Ohmura, Yoshiaki ;
Masuzawa, Toru ;
Takeno, Atsushi ;
Takeda, Yutaka ;
Kato, Takeshi ;
Yamamoto, Aya ;
Toda, Michihito ;
Iwata, Takashi ;
Murata, Kohei .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[23]   A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States [J].
Nevala-Plagemann, Christopher ;
Sama, Shashank ;
Ying, Jian ;
Shen, Jincheng ;
Haaland, Benjamin ;
Florou, Vaia ;
Garrido-Laguna, Ignacio .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 (03) :257-264
[24]   Targeting KRAS G12C with Covalent Inhibitors [J].
Ostrem, Jonathan M. L. ;
Shokat, Kevan M. .
ANNUAL REVIEW OF CANCER BIOLOGY, 2022, 6 :49-64
[25]   Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises [J].
Pervanidis, Kosmas Alexandros ;
D'Angelo, Giovanni Danilo ;
Weisner, Joern ;
Brandherm, Sven ;
Rauh, Daniel .
JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (08) :6052-6063
[26]   Exploring diverse frontiers: Advancements of bioactive 4-aminoquinoli-ne-based molecular hybrids in targeted therapeutics and beyond [J].
Ravindar, Lekkala ;
Hasbullah, Siti Aishah ;
Rakesh, K. P. ;
Raheem, Saki ;
Agustar, Hani Kartini ;
Ismail, Norzila ;
Ling, Lau Yee ;
Hassan, Nurul Izzaty .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 264
[27]   Pyrimidines maintain mitochondrial pyruvate oxidation to support de novo lipogenesis [J].
Sahu, Umakant ;
Villa, Elodie ;
Reczek, Colleen R. ;
Zhao, Zibo ;
O'Hara, Brendan P. ;
Torno, Michael D. ;
Mishra, Rohan ;
Shannon, William D. ;
Asara, John M. ;
Gao, Peng ;
Shilatifard, Ali ;
Chandel, Navdeep S. ;
Ben-Sahra, Issam .
SCIENCE, 2024, 383 (6690) :1484-1492
[28]   Engineering patient-specific cancer immunotherapies [J].
Scheetz, Lindsay ;
Park, Kyung Soo ;
Li, Qiao ;
Lowenstein, Pedro R. ;
Castro, Maria G. ;
Schwendeman, Anna ;
Moon, James J. .
NATURE BIOMEDICAL ENGINEERING, 2019, 3 (10) :768-782
[29]   Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs [J].
Shelton, Jadd ;
Lu, Xiao ;
Hollenbaugh, Joseph A. ;
Cho, Jong Hyun ;
Amblard, Franck ;
Schinazi, Raymond F. .
CHEMICAL REVIEWS, 2016, 116 (23) :14379-14455
[30]   A non-proliferative role of pyrimidine metabolism in cancer [J].
Siddiqui, Aarif ;
Ceppi, Paolo .
MOLECULAR METABOLISM, 2020, 35